Deniban in the treatment of dysthymia;Deniban v léčbě dystymie

Ceska a Slovenska Psychiatrie

Volumn 103, Issue 2, 2007, Pages 73-79

  Ceskova E ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Chronic mild depression; Deniban; Dysthymia

Indexed keywords

AMISULPRIDE; DENIBAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG TOLERABILITY; DYSTHYMIA; FEMALE; GALACTORRHEA; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; MASTALGIA; NAUSEA; OBSERVATIONAL STUDY; OPEN STUDY; SOMNOLENCE; TREATMENT DURATION; TREATMENT OUTCOME; XEROSTOMIA;

EID: 34247144479     PISSN: 12120383     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Amore, M., Jori, M. C.: Faster response on amisulpride 50 mg versus sertraline 50 -100 mg in patients with dysthymia or double depression. Int. Clin. Psychopharmacol., 16, 2001, pp. 317-324.
2. Češková, A.: Amisulprid - nové benzamidové antipsychotikum II. Generace. Čes. a slov. Psychiatrie, 96, 2000, s. 411-415.
3. Češková, E.: Nové aspekty psychiatrické léčby. Čes. a slov. Psychiatrie, 102, 6, 2006, s. 319-322.
4. De Lima, M. S., Hotoph, M., Nesely, S.: The efficacy of drug treatments for dysthymia: a systematic review and meta-analysis. Psychological Medicine, 29, 1999, pp. 1273-1289.
5. Guy, W.: CGI, Clinical Global Impression. In: ECDEU Assessment Manual for Psychopharmacology, (Guy W., ed.), Rockville, M. D: US Department of Health, Education and Welfare, p. 217.
6. Holand, R. H.: Pharmacotherapy of dysthymia: a review. J. Clin. Psychopharmacol., 11, 1991, pp. 83-92.
7. Kessler, R. C., McGonagle, K. A., Zhao, S. et al.: Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry, 51, 1994, pp. 8-19.
8. Klimek, V., Schenck, J. E., Han, H. et al.: Dopaminergic abnormalities in amygdaloid nuclei in major depression: a postmortem study. Biol. Psychiatry, 52, 2002, p. 740-748.
9. Lambert, G., Johansson, M., Agren, H., Friberg, P.: Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch. Gen. Psychiatry, 57, 2000, pp. 337-340.
10. Montgomery, S. A., Asberg, M.: A new depression scale designed to be sensitive to change. Br. J. Psychiatry, 134, 1979, pp. 382-389.
11. Nestler, E. J., Carlezon, W. A.: The mesolimbic dopamine reward circuit in depression. Biol. Psychiatry, 59, 2006, pp. 1151-1159.
12. Neumeister, A., Willemit, M., Praschak-Rieder, N. et al.: Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychol. Med., 31, 2001, pp. 1467-1473.
13. Noble, S., Benfield, P.: Amisulpride: A review of its clinical potential in dysthymia. CNS Drugs, 12, 1999, pp. 471-483.
14. Papakostas, G. I.: Dopaminergic-based pharmacotherapies for depression. Eur. Neuropsychopharmacology, 16, 2006, pp. 391-402.
15. Praško, J., Herman, E., Hovorka, J.: Dystymie a její léčba - 1. díl. Psychiatrie pro praxi, 6, 2002, s. 265-270.
16. Praško, J., Herman, E., Hovorka, J.: Dystymie a její léčba - 2. díl. Psychiatrie pro praxi, 1, 2003, s. 23-28.
17. Rampello, L., Nicoletti, F., Nicoletti, F.: Dopamine and depression. Therapeutic implication. CNS Drugs, 13, 2000, pp. 35-45.
18. Smeraldi, E.: Amisulpride versus fluoxetine in patients with dysthymia or major depression in partial remission. A double-blind comparative study. J. Affect. Disord., 48, 1998, pp. 47-56.
19. Švestka, J.: Nová psychofarmaka. Amisulprid - atypický preparát ve skupině antipsychotik 2. generace. Psychiatry, 4, 2000, s. 91-200.
20. Weissman, M. M., Leaf, P. J., Bruce, M. L., Florio, L.: The epidemiology of dysthymia in five communities: Rates, risks, comorbidity and treatment. Am. J. Psychiatry, 145, 1988, pp. 815-819.